A nthracycline-based chemotherapy is associated with subclinical left ventricular (LV) dysfunction and future cardiovascular events. [1] [2] [3] [4] Previously, elevated cardiovascular magnetic resonance (CMR) measures of extracellular volume (ECV) fraction, a marker of diffuse myocardial fibrosis associated with mortality and heart failure, 5 have been observed among adult cancer survivors.
Elevated T1 and ECV After Anthracycline Treatment cardiovascular comorbidities. To accomplish this, we measured ECV (and its component measures including LV myocardial T1 with and without gadolinium contrast) using CMR among adult cancer survivors previously treated with anthracycline-based chemotherapy. Also, we assessed myocardial T2 mapping measures for myocardial edema. As comparators, we assessed newly diagnosed cancer patients before receipt of chemotherapy, cancer survivors treated with nonanthracycline chemotherapy, and cancer-free control participants with and without risk factors for cardiovascular fibrosis.
Methods

Study Population
A total of 327 participants were placed into 1 of 3 groups: 236 control participants without cancer, 37 cancer participants yet to receive scheduled cancer treatment, and 54 cancer survivors (of whom 37 received anthracycline-based chemotherapy and 17 received nonanthracycline chemotherapy). The 327 individuals were drawn from 2 National Institutes of Health-funded concurrent (years 2010-2012) cohort studies that underwent CMR scanning at Wake Forest Health Sciences on the same scanner and with the same imaging protocol. The first cohort included 224 participants from Examination 5 of the Multi-Ethnic Study of Atherosclerosis (MESA) 8 with no history of cancer. The second cohort included 91 cancer participants consecutively recruited from the Comprehensive Cancer Center at Wake Forest School of Medicine (and 12 healthy community-dwelling comparators). Cancer participants were either scanned before receipt of chemotherapy or after completion and were uniquely classified into one study group (no serial scans included).
All participants who were enrolled in the research studies were approved by the local Institutional Review Board, and all participants provided written, informed consent. From both cohorts, we excluded participants with evidence of myocardial infarction, hypertrophic cardiomyopathy, intracardiac masses, or other cardiovascular infiltrative disorders (eg, amyloidosis or sarcoidosis) that could also alter ECV values.
CMR Imaging Acquisition
All study participants underwent their research CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Systems, Erlangen, Germany) with a phased array chest coil. All participants underwent a noncontrasted CMR examination for evaluation of native T1, LV volumes, and LV mass. Participants with estimated glomerular filtration rates (assessed by serum creatinine levels in blood samples taken from venipuncture before CMR examination) of ≥45 mL/ min received either 0.15 mmol/kg of Magnevist (Bayer Healthcare Pharmaceuticals, Montville, New Jersey; n=184) if in the first cohort (MESA) 8 or 0.2 mmol/kg of ProHance (Bracco Diagnostics, Princeton, New Jersey, n=74) gadolinium contrast if in the second cohort (participants recruited from the Comprehensive Cancer Center). Matching imaging protocols (sequences, parameters, and timing with contrast) on a single scanner were used in both cohorts.
Imaging parameters for all imaging sequences were performed according to previously published techniques. [9] [10] [11] [12] [13] For measurement of LV volumes and mass, short-axis steady-state free precession cine slices were acquired from the cardiac apex to its base. Cine imaging parameters included a 360-to 400-mm field of view collected with a 256×160 matrix, a 20° flip angle, a 6 mm slice thickness with 4 mm slice gap, a 3 to 5 ms echo time, and an 8 to 10 ms repetition time. 14 In participants from the Comprehensive Cancer Center cohort, T2 mapping was collected with a 360×360 field of view, 192×60 matrix, 70° flip angle, 6 mm slice thickness, acceleration factor of 2, and T2 preparation pulses of 0, 24, and 55 ms.
Myocardial T1 mapping was acquired with a modified LookLocker inversion recovery sequence in a midcavity short-axis slice precontrast (native T1) and again at 12 and 25 minutes after contrast administration in contrast eligible participants. [11] [12] [13] The modified Look-Locker inversion imaging acquired 11 images in the span of 17 heartbeats with a 360×360 mm field of view collected with a 192×183 matrix, 35° flip angle, 8 mm slice thickness, 1.1 ms echo time, 2.2 ms repetition time, and an acceleration factor of 2.
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CMR Data Analysis
In accordance with previously published techniques, a 3-parameter curve fit with the Levenberg-Marquardt algorithm was applied to the modified Look-Locker inversion source images to create a T1 map. 13 Myocardial endocardial and epicardial borders were carefully drawn manually on each cine series (at end-diastole and end-systole for LV volumes and mass) and on T1 and T2 maps to ensure exclusion of the LV blood pool and epicardial fat. The average T1 and T2 were calculated from the segmented myocardium; univariate linear modeling was performed to determine T1-related heart rate dependency. 13 For calculation of ECV fraction, a region of interest was placed in the LV blood pool to determine the T1 of blood. Using the 3 time points (precontrast and 12 and 25 minutes postcontrast), the partition coefficient was determined from the slope of 1/T1 myo versus 1/T1 blood and used to calculate ECV as previously described.
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Statistical Analysis
Statistical means and standard deviations were calculated for all continuous variables, and frequencies and percentages were tabulated for all categorical variables. One-way analyses of variance tests were performed to examine between-group differences, and 2-sided Student's t tests were performed to determine a treatment effect between the pretreatment and anthracycline-treated survivor cancer groups. Outcome variables (T1, ECV) were age-adjusted for the mean age of cancer participants using least-squares means. Finally, a series of multivariate model analyses were performed to determine the dependency outcome variables on covariates of participant demographics, cardiovascular profile, and LV remodeling parameters. All analyses were performed in SAS version 9.3 (SAS Institute, Cary, NC) with P<0.05 considered statistically significant.
Results
Participant baseline characteristics are summarized in Table 1 The body habitus was similar across all groups ( Table 1 ). The cancer groups were similar in age but younger than those in the control group without cancer (P<0.0001; Table 1 ). Compared with pretreatment cancer participants, anthracycline-treated cancer participants exhibited a reduced LVEF and trended to have a smaller myocardial mass index (Table 2; P<0.0001 and P=0.06, respectively). The heart rate during T1 mapping was similar in all groups after adjustment for age and sex (P>0.30 for all comparisons). Additionally, among those who received gadolinium, hematocrit values were no different across groups (P=0.10). The published concordance correlation coefficient of T1 and ECV in the MESA study showed excellent agreement among analysts and low interobserver variability (concordance correlation coefficient =0.90-0.96). 16, 17 Analysis of images from the second cohort was performed by one analyst (J.H. Jordan) and over-read by a secondary analyst (G.C. Meléndez), resulting in a mean ECV difference of 0.56±1.6% with a concordance correlation coefficient =0.84, also showing excellent agreement between analysts.
Myocardial native T1 was elevated in pretreatment and posttreatment cancer participants (1058±7 and 1040±7 ms, respectively) compared with controls without cancer (965±3 ms; P<0.0001 for both; Figure 1 ). T2 was within normal ranges for both pretreatment cancer participants (51.7±2 ms) and anthracycline-treated cancer survivors (52.5±4 ms) and was not correlated with native T1 (r=−0.01; P=0.94).
As shown in Figure 2 , ECV was similar among cancer pretreatment and controls (27.8±0.7 versus 26.9±0.2, respectively; P=0. 19 ). However, ECV was elevated in cancer posttreatment participants (30.4±0.7%) compared with similarly aged cancer pretreatment and control participants (P<0.01 for both). Figure 3 shows a representative image from a participant in each study group. There was no measured effect of the contrast agent type or dose on ECV after adjustment for age and sex among comparators (P=0.22). ECV was calculated with 2 postcontrast T1 values; however, no difference was found when compared with ECV calculated with 1 postcontrast T1 value (27.39 versus 27.36%; P=0.40). Additionally, there was no difference in ECV for breast cancer survivors treated with or without radiation therapy (33.2±6.4% versus 33.7%, respectively; P=0.94). No significant ECV elevations were observed in the nonanthracycline breast cancer participants compared with similarly aged pretreatment breast cancer comparators; however, ECV trended higher in anthracycline-treated versus nonanthracycline-treated breast cancer survivors (Figure in the Data Supplement). Table 3 displays the multivariable models used to determine whether covariates known to influence T1 indices were responsible for the statistical difference between the 3 study groups. The baseline models (model 1) examined native T1 or ECV with the study group as a covariate and were found to be significantly different across the groups (P<0.0001 for both). Model 2 added age, race, sex, and an interaction for age×sex to model 1 and again found that native T1 and ECV remained different across the groups (P<0.0001 for both). Model 3 added cardiovascular health and risk factors for cardiovascular events and myocardial fibrosis to model 2, including weight, heart rate, systolic blood pressure, and presence of known coronary artery disease, diabetes mellitus, hyperlipidemia, and hypertension. After accounting for participants' demographics and cardiovascular comorbidities, native T1 and ECV were significantly different across the groups (P<0.0001 for both; model 3). Finally, model 4 added LVEF and LV mass index to model 2. Again, CMR findings consistent with elevated myocardial fibrosis (T1 and ECV) remained elevated even after the adjustments in model 4 (P<0.0001 for both).
Discussion
The results of this study demonstrate several important findings. First, ECV fraction measured with CMR is abnormally increased 3 years after receipt of anthracycline-based chemotherapy above and beyond that which occurs in the presence of cancer before treatment (Figure 2 ). Second, elevated ECV persists even after accounting for preexisting cardiovascular comorbidities associated with subclinical fibrosis development Age-adjusted values expressed as µ ± σ Elevated T1 and ECV After Anthracycline Treatment (Table 3) . Third, myocardial native T1 is elevated 3 years after cancer treatment and before the time individuals with cancer initiate their treatment for cancer. This elevation in T1 occurs with a small but not marked increase in ECV in untreated cancer patients and cancer survivors treated with nonanthracycline chemotherapy. Fourth, our study demonstrates that increased subclinical myocardial fibrosis, as manifest by ECV elevations, coincides with decreases in LVEF and myocardial mass in adult cancer survivors 3 years after receiving anthracycline-based chemotherapy. Previously in a study of adults surviving beyond 7 years from their cancer treatment with clinically indicated CMR examinations, myocardial ECV was elevated compared with healthy adults free of cardiovascular risk factors or cancer. 6 In 2 studies of asymptomatic pediatric cancer survivors, myocardial T1 and ECV were within normal ranges for younger populations; however, in these same studies, ECV was associated with cumulative anthracycline dose, reduced exercise capacity, myocardial wall thinning, increased end-systolic fiber stress, and reduced LV myocardial contractility. 18, 19 These prior studies did not address whether (1) the ECV elevations were related to other cardiovascular comorbidities also associated with subclinical myocardial fibrosis or (2) the presence of cancer in and of itself.
Our results indicate elevation of ECV 3±1 years (as opposed to the previously reported 7 years) after receipt of anthracycline-based chemotherapy (Figure 2 ). The magnitude of the elevation (30±1%) was greater than in patients with cardiovascular comorbidities without cancer (27±0.2%) and in those yet to initiate their cancer treatment (28±1%) but lower than in the previously reported 7-year survivors (36±3%). 6 Differences in ECV between the cancer groups are not likely 20 ; however, it is unknown if ECV measures of fibrosis may be detected this early. A future longitudinal cohort study performed in patients before, during, and after cancer treatment could address these issues.
Our study design allowed us to compare ECV values in our survivor population with ECV values from those enrolled in the MESA cohort that possess risk factors for cardiovascular events and myocardial fibrosis. 21 Selection of MESA as the comparator cohort was based on (1) similar CMR protocol to the study cohort and (2) requirement of a comparator because no cancer-free comparator subgroup (with and without cardiovascular comorbidities) with contemporary T1 and ECV data was available. Interstitial myocardial fibrosis, assessed by ECV, is known to increase with age and, in general, is higher among women. 11 In this study, we identified that ECV remained elevated in survivors after accounting for age, sex, and their interaction using multivariable models (Table 3) ; similar results were found in a sensitivity analysis with propensity score matching on factors that influence T1. These data suggest that the ECV elevation we observed in survivors previously treated with anthracycline-based chemotherapy was not dependent on age or sex.
In addition, we performed other models that included cardiovascular comorbidities and LV remodeling measures, such as LVEF or mass. As shown in Table 3 , ECV remained elevated relative to those without cancer after accounting for weight, heart rate, systolic blood pressure, known coronary arterial disease, diabetes mellitus, hyperlipidemia, hypertension, LVEF, and LV mass index. These data confirm that elevations of ECV, a strong indicator of subclinical myocardial fibrosis, occur 3 years after receipt of anthracycline-based chemotherapy independent of other cardiovascular comorbidities previously associated with progressive LV myocardial fibrosis. LV myocardial ECV increases with age, and the ECV of untreated cancer patients was similar to controls who were 10 years older.
To measure ECV, we calculated LV myocardial T1 before (native T1) and after the administration of gadolinium contrast ( Figure 3) . Overall, native T1 and ECV values of our comparator noncancer group are similar to those previously reported in the literature. 11, 22 As expected, elevated native T1 coincided with elevated ECV among cancer survivors (Table 3) . We included an exploratory analysis of nonanthracycline breast cancer survivors that showed an intermediate ECV between comparators and anthracycline-treated survivors; these preliminary findings should be further investigated in a larger study powered to determine the relationship of nonanthracycline chemotherapy with changes in myocardial fibrosis. Interestingly, we found that newly diagnosed cancer patients exhibited elevated native T1 but their ECV elevation was far less than that of survivors who received anthracycline-based chemotherapy. T2 was within normal limits in anthracycline-treated cancer survivors (52.5 ms) and, thus, indicates that their increased ECV is more likely related to myocardial fibrosis and not increased water content or myocardial edema.
It is important to note that ECV reflects interstitial processes that influence T1, whereas native T1 may reflect changes in myocellular composition (eg, intra-myocellular edema or deposition of protein, lipids, or iron), interstitial processes, and changes in myocardial oxygenation or perfusion. 23, 24 Previously, both skeletal and cardiac muscles have demonstrated increased intracellular edema related to inflammatory cytokines associated with cancer before treatment. 25 Thus, our observation of T1-related changes in newly diagnosed cancer patients may be related to the presence of comorbidities, cancer-related processes, or a mixture of both. Our findings of reduced LVEF and LV mass loss in adult survivors treated with anthracyclines are consistent with prior reports. [26] [27] [28] The higher LV mass among cancer-free comparators is likely age-related. Neilan et al reported reduced LV mass and LVEF in anthracycline-treated survivors with elevated ECV, 6 and lower LV mass was related to increased risk for cardiovascular events in survivors with anthracycline-induced cardiomyopathy. 26 Importantly, LV mass is determined during CMR by measuring the myocardial volume residing between the epi-and endocardial contours from 3-dimensional image acquisitions spanning the cardiac apex to its base planned in the LV short-axis plane. 9 This tissue volume is multiplied by a widely accepted specific density constant for normal myocardial tissue. In the setting of abnormal myocardial tissue-as in anthracycline cardiotoxicity-the true LV myocellular mass may be underestimated when replaced by fibrous tissue. Thus, these study results indicate that not only do 3-year cancer anthracycline-treated survivors have a reduced LV mass, but also 30% of the tissue categorized as mass is actually extramyocellular volume that does not include functioning cardiac myocytes.
These study results have important clinical ramifications. Myocardial extracellular remodeling with increased collagen and fibrosis stiffens the LV and, in other populations, contributes to LV dysfunction, fatigue, and reduced exercise capacity. [29] [30] [31] To date, most anthracycline cardiotoxicity research has focused on myocellular injury. The 3-year posttreatment ECV elevation warrants additional research to investigate the time course of onset and the clinical importance of myocardial fibrosis and whether it relates to the cardiovascular mortality and exercise intolerance observed in cancer survivors. 18, 32 Current surveillance strategies focused only on LVEF after symptoms could miss the onset of subclinical fibrosis, 3, 33 and therapies for fibrosis differ from those that prevent myocellular injury. 34 Our results are interpreted in the setting of the following limitations. First, our cross-sectional analysis does not allow us to determine the time course of ECV elevation among individuals treated for cancer. A prospective longitudinal study with matched control participants would aid in understanding the time course of myocardial fibrosis development, inflammatory processes, LV functional deterioration, and associations with cardiovascular events. Second, only 69% of cancer patients exhibited estimated GFR values ≥45 mL/min and consented to receipt of contrast; thus, we are uncertain of the assessment of ECV in those with reduced GFR values. Third, 2 different contrast agents were administered in the study with a mild decrease in dose for the cancer participants. ECV assessments comparing other types of gadolinium-contrast agents observed a mean ECV difference of only 0.01% 35 ; a similar effect in this study would not alter our observation of elevated ECV in anthracycline-treated survivors. Furthermore, we found no significant effect of the contrast agent and dose on ECV measurements among control participants. Future prospective studies could use a single contrast agent and dose to eliminate this potential confounder.
In conclusion, in adult cancer survivors treated with anthracycline-based chemotherapy, myocardial ECV-a marker of diffuse fibrosis-is abnormally elevated 3 years after treatment. This elevation occurs after accounting for other risk factors, such as age, the presence of cancer, or coexistent cardiovascular comorbidities, thereby suggesting that receipt of anthracyclinebased chemotherapy is associated with the adverse accumulation of LV interstitial myocardial fibrosis in cancer survivors.
